Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Patent Office (EPO) has issued Notice of Allowance to Amarantus Therapeutics. The patent application claims include the discovery of mesencephalic astrocyte-derived neurotrophic factor (MANF) and also include compositions of matter and methods of use for MANF, and other related compounds.
Subscribe to our email newsletter
Amarantus claimed that MANF is a highly potent, neurotrophic factor currently in pre-clinical development for the treatment of a range of diseases that includes Parkinson’s disease.
Amarantus said that the patent will broaden overall protection for the its therapeutic development of MANF.
Martin Cleary, CEO of Amarantus, said: “This initial patent allowance from the EPO is a major milestone for the company’s intellectual property pursuits and significantly strengthens our proprietary position in the field.
“Moreover, this latest patent will further protect Amarantus’ intellectual property as the company expands its pipeline of first-in-class therapeutics to address a number of indications.
“Additionally, we will continue to build a strong intellectual property portfolio around our proprietary technology and to further strengthen our leadership position in the emerging field of novel therapeutics.”